Because of donors like you, we’re able to take bold legal action. Join us in continuing the fight—donate here.
Just two months after the COVID-19 vaccine rollout, FDA granted Pfizer approval to start marketing its drug, Panzyga, for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a life-threatening neurological autoimmune condition. CIDP has since been documented as a serious adverse reaction to the mRNA vaccines.
Back in April of 2020, before its COVID-19 vaccine human clinical trials started, Pfizer submitted an application to FDA asking to market its immunodeficiency drug, Panzyga, as a treatment for CIDP. Could data from Pfizer’s COVID-19 vaccine preclinical animal trials have pointed to neurological issues (such as CIDP) even then, possibly prompting Pfizer’s desire to market this drug for that condition?
Coincidentally, FDA sat on Pfizer’s request to market Panzyga for CIDP for almost a year before suddenly approving it on February 12, 2021. At that point, the COVID-19 vaccine had been rolled out to over 42 million Americans and the V-safe and VAERS data was rolling in. FDA may have seen an early safety signal for CIDP and recognized the need for the drug.
At that point in time, Maddie de Garay had been injured in Pfizer’s clinical trial for ages 12-15, and Brianne Dressen had been injured in AstraZeneca’s adult clinical trial. Maddie and Brianne’s cases would become among the most well-known cases of COVID-19 vaccine-related CIDP.
Rest assured, ICAN’s attorneys are already on the case and have requested all documents FDA relied upon to approve Panzyga to treat CIDP. We will be sure to update you on our findings.
To support future legal actions like this, click here to donate!
